REN46332 Marker Search Result - Rat Genome Database

Help | FTP Download | Citing RGD | Contact Us

Keyword

General

Marker: REN46332

Symbol:

REN46332

Also known as:

Expected Size:

226 (bp)

Position

Map	Chr	Position	Source
Human Genome Assembly HuRef	2	226,378,868 - 226,379,093	UniSTS
Human Genome Assembly GRCh37	2	234,578,865 - 234,579,090	UniSTS
Human Celera Assembly	2	228,299,496 - 228,299,721	RGD
Human Genome Assembly Build 36	2	234,243,604 - 234,243,829	RGD
Human Cytogenetic Map	2	q37	UniSTS

Is Marker For:

Genes: UGT1A10 UGT1A8 UGT1A9

Model

Launch Genome Browser (GBrowse) : build 36 (hg18) , build 37 (hg19)

Annotation

References - curated

Strains and Sequence

Sequence

Region

Genes in Region (Human Genome Assembly GRCh37)

Nucleotide Sequences

QTLs in Region (Human Genome Assembly GRCh37)

The following QTLs overlap with this region.

RGD ID	Symbol	Name	LOD	P Value	Trait	Sub Trait	Chr	Start	Stop	Species
1578607	COARD5_H	Coronary artery disease susceptibility QTL 5 (human)	2.63	.0002	Coronary artery disease susceptibility		2	198714649	240901754	Human
2316066	GLUCO201_H	Glucose level QTL 201 (human)		.008	Glucose level		2	209017112	235017112	Human
2293468	PRSTS292_H	Prostate tumor susceptibility QTL 292 (human)		.013	Prostate tumor susceptibility		2	211696915	237696915	Human
2293478	PRSTS301_H	Prostate tumor susceptibility QTL 301 (human)		.002	Prostate tumor susceptibility		2	211696915	237696915	Human
2293483	PRSTS283_H	Prostate tumor susceptibility QTL 283 (human)			Prostate tumor susceptibility		2	211696915	237696915	Human
1331635	COPD19_H	Chronic obstructive pulmonary disease QTL 19 (human)	4.12		Chronic airflow obstruction	FEV1/FVC ratio	2	214579907	238078645	Human
2289332	BW376_H	Body weight QTL 376 (human)	1.87	.00168	Body fat amount	abdominal	2	214629769	240629769	Human
1643044	BW151_H	Body weight QTL 151 (human)		.0045	Body fat amount	percent body fat	2	216180297	242180297	Human
1298412	RA1_H	Rheumatoid arthritis QTL 1 (human)		.0141	Joint/bone inflammation	rheumatoid arthritis	1	217683765	243062293	Human
2315762	GLUCO151_H	Glucose level QTL 151 (human)	1.26	.0079	Glucose level		2	217683765	243062293	Human
2289209	BW347_H	Body weight QTL 347 (human)		.0123	Body fat amount	percent fat	2	218172688	243062293	Human
1643566	GLUCO16_H	Glucose level QTL 16 (human)	.61	.047	Glucose level	non-insulin-dependent	2	219206386	243062293	Human
2292834	PRSTS26_H	Prostate tumor susceptibility QTL 26 (human)			Prostate tumor susceptibility	early onset	2	219206386	243062293	Human
2289437	BW401_H	Body weight QTL 401 (human)	1.95		Body fat amount	percent fat	2	220707942	243062293	Human
1643501	BW261_H	Body weight QTL 261 (human)	1.5	.00482	Body weight	body mass index	2	220950848	243062293	Human
2315056	GLUCO134_H	Glucose level QTL 134 (human)	2.18		Glucose level		2	222777148	243062293	Human
1559407	SCL113_H	Serum cholesterol level QTL 113 (human)	2.31		Lipid level	LDL-HDL ratio	2	224235556	243062293	Human
2302776	MAMTS12_H	Mammary tumor susceptibility QTL 12 (human)		.046	Mammary tumor susceptibility		2	224235556	243062293	Human
2289589	BW465_H	Body weight QTL 465 (human)	2.4		Body weight	lean mass	2	227293057	237235700	Human
2315772	GLUCO146_H	Glucose level QTL 146 (human)	3.03	.002	Glucose level		2	228168147	243062293	Human
1358856	MULTSCL17_H	Multiple sclerosis susceptibility QTL 17 (human)			Multiple sclerosis susceptibility		2	228739542	243062293	Human
2315054	GLUCO132_H	Glucose level QTL 132 (human)	1.97		Glucose level		2	229853452	243062293	Human
2315066	GLUCO131_H	Glucose level QTL 131 (human)	3.19	.00058	Glucose level		2	229853452	243062293	Human
2293463	PRSTS293_H	Prostate tumor susceptibility QTL 293 (human)		.012	Prostate tumor susceptibility		2	232206264	238078645	Human
2315804	GLUCO166_H	Glucose level QTL 166 (human)	1.87	.0017	Glucose level		2	233707822	237235700	Human

Additional Information

External Database Links

More on REN46332
	Genome Browser:	(hg18) (hg19)
	Ensembl
	NCBI

RGD Object Information
RGD ID:	1950960
Created:	2008-01-13
Species:	Homo sapiens
Last Modified:	2013-06-11
Status:	ACTIVE